MedTrace Logo

Fuzeon Viral Decay Pilot Study

NCT00334022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-06-05

No results posted yet for this study

Summary

In order to better understand the source(s) and the mechanism(s) of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs, we propose to examine the effect of co-administration of enfuvirtide, an entry inhibitor of HIV, on diminution of the size of the viral reservoir in infected individuals who are receiving effective antiviral therapy for extended periods of time (\> 5 years).

Conditions

Interventions

DRUG

enfuvirtide

1ml BID

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Canadian Immunodeficiency Research Collaborative

    lead OTHER

Principal Investigators

  • Colin Kovacs, MD · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-07-31
Completion
2010-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334022 on ClinicalTrials.gov